Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:ageOfUse |
from 2 weeks of age
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States |
| gptkbp:containsAntigen |
porcine circovirus type 2 ORF2 protein
|
| gptkbp:durationOfImmunity |
at least 23 weeks after vaccination
|
| gptkbp:form |
suspension for injection
1 ml per pig |
| https://www.w3.org/2000/01/rdf-schema#label |
Ingelvac CircoFLEX
|
| gptkbp:indication |
reduction of lymphoid lesions caused by PCV2
reduction of viraemia caused by PCV2 reduction of virus shedding caused by PCV2 |
| gptkbp:manufacturer |
gptkb:Boehringer_Ingelheim
|
| gptkbp:marketingAuthorizationHolder |
Boehringer Ingelheim Vetmedica GmbH
|
| gptkbp:routeOfAdministration |
intramuscular
|
| gptkbp:sideEffect |
mild transient increase in body temperature
mild transient swelling at injection site |
| gptkbp:species |
swine
|
| gptkbp:storage |
2°C to 8°C
|
| gptkbp:usedFor |
prevention of porcine circovirus type 2 (PCV2) infection
|
| gptkbp:bfsParent |
gptkb:Boehringer_Ingelheim_Animal_Health
|
| gptkbp:bfsLayer |
7
|